By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name China Biologic Products Holdings, Inc.
Stock ticker CBPO
Live stock price [stckqut]CBPO[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Fair

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $130.58
Target stock price (averages with growth) $135.88
Target stock price (averages with no growth) $92.3
Target stock price (manual assumptions) $121.87

 

The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/cbpo

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing, and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.

The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC). The Company offers human albumin for the treatment of shock caused by blood loss trauma or burn, raised intracranial pressure caused by hydrocephalus or trauma, edema or ascites caused by hepatocirrhosis and nephropathy, prevention and treatment of low-density-lipoproteinemia, and neonatal hyperbilirubinemia. It offers human immunoglobulin and IVIG for the treatment of original immunoglobulin deficiency, such as X chain low immunoglobulin, familiar variable immune deficiency, immunoglobulin G secondary deficiency, secondary immunoglobulin deficiency, such as infection and newborn sepsis, and auto-immune deficiency diseases, such as original thrombocytopenia purpura or kawasaki disease. It offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis. It offers human rabies immunoglobulin for passive immunity from bites or claws by rabies or other infected animals. It offers human tetanus immunoglobulin for the prevention and therapy of tetanus. It offers placenta polypeptide for the treatment for cell immunity deficiency diseases, viral infection and leucopenia caused by various reasons, and also in postoperative healing. It offers Factor VIII for the treatment for coagulopathies, such as hemophilia A and increased concentration of coagulation factor VIII. It offers PCC for the treatment of congenital and acquired clotting factor II, VII, IX, X deficiency, such as Hemophilia B, excessive anticoagulant, and vitamin K deficiency.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in China Biologic Products Holdings, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of China Biologic Products Holdings, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $84.52
  • Growth: 0.15
  • Current EPS (TTM): $2.38
  • P/E: 41
  • Future EPS Calc: $4.78
  • Future Stock Price Calc: $196.26
  • Target stock price: $121.86

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name Methode Electronics Inc.
Stock ticker MEI
Live stock price [stckqut]MEI[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Poor
EPS growth Good
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $40.91
Target stock price (averages with growth) $41.75
Target stock price (averages with no growth) $22.7
Target stock price (manual assumptions) $42.72

 

The following company description is from Google Finance: https://finance.google.com/finance?q=mei

Methode Electronics, Inc. (Methode) is a manufacturer of component and subsystem devices. The Company designs, manufactures and markets devices employing electrical, radio remote control, electronic, wireless and sensing technologies. The Company operates through segments, including Automotive, Interface, Power Products and Other. The Automotive segment supplies electronic and electro-mechanical devices and related products to automobile original equipment manufacturers (OEMs). The Interface segment provides a range of copper and fiber-optic interface and interface solutions. The Power Products segment manufactures braided flexible cables, current-carrying laminated bus devices, custom power-product assemblies, such as PowerRail solution, high-current low voltage flexible power cabling systems and powder coated bus bars. The Other segment includes medical devices, inverters and battery systems, and insulated gate bipolar transistor solutions.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Methode Electronics Inc. as long as the price is correct and the indicators that I describe in my book The Confident Investor are favorable. Most of the fundamentals of this company are good but there are some concerns. Because of these concerns, I am removing Methode Electronics from my Watch List.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Methode Electronics Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $40.1
  • Growth: 0.12
  • Current EPS (TTM): $2.44
  • P/E: 16
  • Future EPS Calc: $4.3
  • Future Stock Price Calc: $68.8
  • Target stock price: $42.72

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Around the web
With: 0 Comments

Today is Tax Day. You may have already paid your taxes and told the government how much you earned and therefore paid. However, if you haven’t done it before today – you need to settle up with the US Government (and most states/cities/counties/etc.). With April 18 finally here, U.S. taxpayers are likely asking themselves:

Where exactly are my tax dollars going?

 

To answer the question, here is a “Taxpayer Receipt” showing how each $100 of taxes was spent, both for 2016 and five years earlier. It was prepared by the Committee for a Responsible Federal Budget (CRFB), a nonpartisan nonprofit group in Washington that monitors federal spending. The group’s three chairmen are Republican Mitch Daniels, Democrat Leon Panetta and independent Tim Penny.

Looking at the list of expenditures, it is clear why some say the U.S. is a giant insurance company with an army. Half of all spending goes for Social Security benefits and health programs such as Medicare and Medicaid, while another 20% is for defense and military benefits.

In the last five years, the shares of spending for Social Security, Medicare and Medicaid have each risen more than 15%. Social Security and Medicare increased largely due to the aging of the population, while the increase in Medicaid comes from aging, growth in health-care costs and expanded eligibility under the Affordable Care Act, also known as Obamacare.

Over the same period, the share devoted to national defense dropped 22%, in part because Congress reduced war spending and capped other military spending in 2011, according to CRFB senior staffer Marc Goldwein.

The tax figures include all federal revenue. The individual income tax provided nearly half the total (47%), while payroll taxes kicked in about one-third (34%). The rest came from corporate income taxes (9%) and other levies such as customs duties and excise taxes (9%).

Source: How $100 of Your Taxes Are Spent: 8 Cents on National Parks and $15 on Medicare – WSJ

By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

Company name Methode Electronics Inc.
Stock ticker MEI
Live stock price [stckqut]MEI[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Poor
EPS growth Good
P/E growth Fair
EBIT growth Good

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $54.89
Target stock price (averages with growth) $54.67
Target stock price (averages with no growth) $25.06
Target stock price (manual assumptions) $49.42

The following company description is from Google Finance: http://www.google.com/finance?q=mei

Methode Electronics, Inc. (Methode) is a manufacturer of component and subsystem devices. The Company designs, manufactures and markets devices employing electrical, radio remote control, electronic, wireless and sensing technologies. The Company operates through segments, including Automotive, Interface, Power Products and Other. The Automotive segment supplies electronic and electro-mechanical devices and related products to automobile original equipment manufacturers (OEMs). The Interface segment provides a range of copper and fiber-optic interface and interface solutions. The Power Products segment manufactures braided flexible cables, current-carrying laminated bus devices, custom power-product assemblies, such as PowerRail solution, high-current low voltage flexible power cabling systems and powder coated bus bars. The Other segment includes medical devices, inverters and battery systems, and insulated gate bipolar transistor solutions.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Methode Electronics Inc. as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Methode Electronics Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $36.16
  • Growth: 0.17
  • Current EPS (TTM): $2.2
  • P/E: 16.5
  • Future EPS Calc: $4.82
  • Future Stock Price Calc: $79.58
  • Target stock price: $49.41

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Around the web
Tagged:
With: 0 Comments

Facebook [stckqut]FB[/stckqut] has reported its first quarter 2016 earnings with $5.38 billion in revenue and earnings per share of $0.52. Much of the revenue ($5.2 billion) came from advertising — a 57 percent annual increase — of which 82 percent was through mobile. The social networking company now counts more than 1.65 billion monthly active users.

The company’s financial results beat Wall Street analysts’ expectations, which estimated $5.26 billion in revenue and an EPS of $0.40. In the same period a year ago, Facebook missed expectations with revenue of $3.54 billion and an EPS of $0.42.

Facebook’s revenue may have fallen from last quarter, but it’s still up 40 percent from the previous quarter last year. The average revenue per user (ARPU) for the quarter was $3.32, down from last quarter’s $3.73, but it was an increase from the $2.50 a year ago.

Facebook has rolled out quite a few options for businesses, and the company has been named the “undisputed leader in mobile advertising” by mobile analytics company AppsFlyer. According to mobile analytics company Kenshoo, the social networking company’s ad platform holds great appeal for brands. It found that social ad spending increased 8 percent quarter over quarter, improving 86 percent annually thanks to the introduction of Facebook Dynamic Product Ads as well as more inventory on Instagram (including longer videos for advertisers) and other properties.

And the company isn’t done offering more advertising opportunities. It will soon make inventory available within its popular messaging service and also in livestreamed video, seemingly the most recent hotbed of competition as Facebook challenges Twitter’s Periscope for dominance.

In a statement, chief executive Mark Zuckerberg said, “We had a great start to the year. We’re focused on our 10 year roadmap to give everyone in the world the power to share anything they want with anyone.”

This 10-year plan Zuckerberg references is the one he unveiled at this month’s F8 developer conference, which showcased how his company is looking beyond the social network and how it will continue to connect people in more ways.

Source: Facebook reports $5.38 billion in revenue, 79% from mobile advertising | VentureBeat | Business | by Ken Yeung